Goldman Sachs Maintains Shire PLC (ADR) to Buy

Brokerage firm Goldman Sachs Maintains its rating on Shire PLC (ADR)(NASDAQ:SHPG). The shares have been rated Buy. The rating by Goldman Sachs was issued on Jun 28, 2016.

In a different note, On Jun 3, 2016, Morgan Stanley said it Assumes its rating on Shire PLC (ADR). The shares have been rated ‘Overweight’ by the firm. On Jun 3, 2016, Jefferies said it Maintains its rating on Shire PLC (ADR). In the research note, the firm Rau the price-target to $223.00 per share. The shares have been rated ‘Buy’ by the firm. Stifel Nicolaus said it Initiates Coverage on Shire PLC (ADR), according to a research note issued on May 26, 2016. The shares have been rated ‘Buy’ by the firm. Bryan Garnier said it Initiates Coverage on Shire PLC (ADR), according to a research note issued on May 23, 2016. The shares have been rated ‘Buy’ by the firm. On May 20, 2016, JP Morgan said it Maintains its rating on Shire PLC (ADR). In the research note, the firm Raises the price-target to $230.00 per share. The shares have been rated ‘Overweight’ by the firm. On May 2, 2016, Leerink Swann said it Maintains its rating on Shire PLC (ADR). In the research note, the firm Raises the price-target to $221.00 per share. The shares have been rated ‘Outperform’ by the firm.

Shire PLC (ADR) (SHPG) made into the market gainers list on Fridays trading session with the shares advancing 1.05% or 1.93 points. Due to strong positive momentum, the stock ended at $186.01, which is also near the day’s high of $187.085. The stock began the session at $186.95 and the volume stood at 17,40,716 shares. The 52-week high of the shares is $270.63 and the 52 week low is $147.6. The company has a current market capitalization of $36,715 M and it has 19,73,80,100 shares in outstanding.

Shire PLC (ADR)(SHPG) last announced its earnings results on Apr 29, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $1.71B. Analysts had an estimated revenue of $1.71B. Earnings per share were $3.19. Analysts had estimated an EPS of $3.05.

Shire plc is a biopharmaceutical company. The Company along with its subsidiaries is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience Gastrointestinal (GI) Rare Diseases and Other therapeutic areas. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate) ADDERALL XR (mixed salts of a single-entity amphetamine) INTUNIV (extended release guanfacine) EQUASYM (methylphenidate hydrochloride) modified release (XL) BUCCOLAM LIALDA (mesalamine)/ MEZAVANT(mesalazine) PENTASA (mesalamine) RESOLOR (prucalopride) REPLAGAL (agalsidase alfa) VPRIV (velaglucerase alfa) FIRAZYR (icatibant) CINRYZE C1 esterase inhibitor (human) FOSRENOL (lanthanum carbonate) XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *